Cyndeo Wealth Partners LLC Buys 564 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Cyndeo Wealth Partners LLC increased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 7.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,379 shares of the medical equipment provider’s stock after acquiring an additional 564 shares during the quarter. Cyndeo Wealth Partners LLC’s holdings in Intuitive Surgical were worth $4,116,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Ullmann Wealth Partners Group LLC increased its holdings in Intuitive Surgical by 1.6% in the 3rd quarter. Ullmann Wealth Partners Group LLC now owns 1,329 shares of the medical equipment provider’s stock valued at $653,000 after buying an additional 21 shares during the period. One Wealth Management Investment & Advisory Services LLC boosted its stake in shares of Intuitive Surgical by 3.4% in the 2nd quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock valued at $310,000 after purchasing an additional 23 shares in the last quarter. Daymark Wealth Partners LLC boosted its stake in shares of Intuitive Surgical by 0.3% in the 3rd quarter. Daymark Wealth Partners LLC now owns 7,027 shares of the medical equipment provider’s stock valued at $3,452,000 after purchasing an additional 24 shares in the last quarter. Indiana Trust & Investment Management CO boosted its stake in shares of Intuitive Surgical by 5.3% in the 2nd quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after purchasing an additional 25 shares in the last quarter. Finally, Hoxton Planning & Management LLC boosted its stake in shares of Intuitive Surgical by 4.9% in the 2nd quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock valued at $238,000 after purchasing an additional 25 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Trading Up 10.0 %

Intuitive Surgical stock opened at $521.15 on Friday. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $523.34. The company has a market cap of $184.85 billion, a PE ratio of 94.07, a PEG ratio of 5.40 and a beta of 1.39. The company’s 50-day moving average is $483.85 and its two-hundred day moving average is $438.17.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. The business had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. Intuitive Surgical’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same period last year, the company posted $1.18 EPS. Research analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Insiders Place Their Bets

In other news, insider Mark Brosius sold 2,115 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $491.91, for a total value of $1,040,389.65. Following the completion of the transaction, the insider now owns 295 shares of the company’s stock, valued at $145,113.45. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Intuitive Surgical news, insider Mark Brosius sold 2,115 shares of Intuitive Surgical stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the transaction, the insider now directly owns 295 shares in the company, valued at approximately $145,113.45. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Craig H. Barratt sold 1,400 shares of the stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total value of $641,382.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 53,120 shares of company stock worth $25,528,753. Company insiders own 0.90% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on ISRG shares. Mizuho boosted their target price on shares of Intuitive Surgical from $440.00 to $500.00 in a research note on Thursday. Evercore ISI restated a “cautious” rating on shares of Intuitive Surgical in a research note on Friday. Citigroup upped their price target on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Royal Bank of Canada upped their price target on shares of Intuitive Surgical from $525.00 to $555.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Oppenheimer reiterated a “market perform” rating on shares of Intuitive Surgical in a research report on Friday. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus price target of $513.74.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.